Insilico Medicine has entered into a multi-year R&D collaboration with Servier worth up to $888 million. The agreement focuses on the discovery and development of new oncology therapies for challenging targets. Insilico will use its proprietary AI platform, Pharma.AI, to identify and advance potential drugs that meet pre-defined scientific criteria. Insilico is eligible for up to $32 million in upfront and short-term research and development payments. Servier participates in the sharing of research and development costs. Once drug candidates are successfully identified, Servier will lead clinical validation, regulatory interactions and global commercialization. This strategic alliance combines Insilico's AI technology with Servier's global oncology expertise.[1]